界定罕见儿科疾病治疗的价值。 - Suppr

Defining the Value of Treatments of Rare Pediatric Conditions.

作者信息

Prosser Lisa A

机构信息

Child Health Evaluation and Research Center, Department of Pediatrics and Communicable Diseases, Medical School, University of Michigan, Ann Arbor.

Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor.

出版信息

JAMA Pediatr. 2018 Dec 1;172(12):1123-1124. doi: 10.1001/jamapediatrics.2018.3343.

DOI:10.1001/jamapediatrics.2018.3343

PMID:30304346

Abstract

摘要

相似文献

Defining the Value of Treatments of Rare Pediatric Conditions.

JAMA Pediatr. 2018 Dec 1;172(12):1123-1124. doi: 10.1001/jamapediatrics.2018.3343.

Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia.

Trends Mol Med. 2018 Sep;24(9):729-731. doi: 10.1016/j.molmed.2018.06.007. Epub 2018 Jul 4.

[Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].

Rinsho Ketsueki. 2018;59(10):1948-1954. doi: 10.11406/rinketsu.59.1948.

Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.

Transfusion. 2018 Jun;58(6):1414-1420. doi: 10.1111/trf.14569. Epub 2018 Mar 13.

First Chimeric Antigen Receptor T-Cell Therapy Approved.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx251.

A Growing Problem of Critical Illness Due to Chimeric Antigen Receptor T-Cell Therapy.

Crit Care Med. 2018 Nov;46(11):e1086-e1087. doi: 10.1097/CCM.0000000000003374.

Only the best CAR T cells.

Nat Rev Clin Oncol. 2018 Jul;15(7):402-403. doi: 10.1038/s41571-018-0039-6.

Chimeric Antigen Receptor T-Cell Therapy: Are Neuroradiologists Prepared?

AJNR Am J Neuroradiol. 2019 Oct;40(10):E52. doi: 10.3174/ajnr.A6186. Epub 2019 Sep 19.

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.

Nat Rev Clin Oncol. 2018 Apr;15(4):218. doi: 10.1038/nrclinonc.2018.20. Epub 2018 Feb 13.

Beginning the CAR T cell therapy revolution in the US and EU.

Curr Res Transl Med. 2018 May;66(2):62-64. doi: 10.1016/j.retram.2018.03.004. Epub 2018 Apr 12.

引用本文的文献

Economic Evaluation of Newborn Screening for Severe Combined Immunodeficiency.

Int J Neonatal Screen. 2022 Jul 20;8(3):44. doi: 10.3390/ijns8030044.

Perceived utility and disutility of genomic sequencing for pediatric patients: Perspectives from parents with diverse sociodemographic characteristics.

Am J Med Genet A. 2022 Apr;188(4):1088-1101. doi: 10.1002/ajmg.a.62619. Epub 2022 Jan 3.

Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights.

Genet Med. 2021 Jul;23(7):1366-1371. doi: 10.1038/s41436-021-01124-x. Epub 2021 Mar 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Defining the Value of Treatments of Rare Pediatric Conditions.

JAMA Pediatr. 2018 Dec 1;172(12):1123-1124. doi: 10.1001/jamapediatrics.2018.3343.

Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia.

Trends Mol Med. 2018 Sep;24(9):729-731. doi: 10.1016/j.molmed.2018.06.007. Epub 2018 Jul 4.

[Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].

Rinsho Ketsueki. 2018;59(10):1948-1954. doi: 10.11406/rinketsu.59.1948.

Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.

Transfusion. 2018 Jun;58(6):1414-1420. doi: 10.1111/trf.14569. Epub 2018 Mar 13.

First Chimeric Antigen Receptor T-Cell Therapy Approved.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx251.

A Growing Problem of Critical Illness Due to Chimeric Antigen Receptor T-Cell Therapy.

Crit Care Med. 2018 Nov;46(11):e1086-e1087. doi: 10.1097/CCM.0000000000003374.

Only the best CAR T cells.

Nat Rev Clin Oncol. 2018 Jul;15(7):402-403. doi: 10.1038/s41571-018-0039-6.

Chimeric Antigen Receptor T-Cell Therapy: Are Neuroradiologists Prepared?

AJNR Am J Neuroradiol. 2019 Oct;40(10):E52. doi: 10.3174/ajnr.A6186. Epub 2019 Sep 19.

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.

Nat Rev Clin Oncol. 2018 Apr;15(4):218. doi: 10.1038/nrclinonc.2018.20. Epub 2018 Feb 13.

Beginning the CAR T cell therapy revolution in the US and EU.

Curr Res Transl Med. 2018 May;66(2):62-64. doi: 10.1016/j.retram.2018.03.004. Epub 2018 Apr 12.

引用本文的文献

Economic Evaluation of Newborn Screening for Severe Combined Immunodeficiency.

Int J Neonatal Screen. 2022 Jul 20;8(3):44. doi: 10.3390/ijns8030044.

Perceived utility and disutility of genomic sequencing for pediatric patients: Perspectives from parents with diverse sociodemographic characteristics.

Am J Med Genet A. 2022 Apr;188(4):1088-1101. doi: 10.1002/ajmg.a.62619. Epub 2022 Jan 3.

Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights.

Genet Med. 2021 Jul;23(7):1366-1371. doi: 10.1038/s41436-021-01124-x. Epub 2021 Mar 25.

Defining the Value of Treatments of Rare Pediatric Conditions.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Defining the Value of Treatments of Rare Pediatric Conditions.

作者信息

机构信息

出版信息

相似文献

引用本文的文献